

Third Program In The Series

# **Ensuring Subject Protection and Scientific Integrity**

#### **Course Introduction Monitoring of Clinical Studies**

Introduction Site Initiation Visit: Initiation Visit Planning Site Initiation Visit: Conducting the Initiation Visit Site Initiation Visit: Initiation Visit Follow-up **Routine Monitoring Visits** How Much Data Needs To Be Monitored? Final Monitoring Visit Changing Data in Case Report Forms Monitoring Reporting Requirements

## Clinical Quality Assurance (CQA)

Introduction Typical CQA Group CQA Audits **GCP** Audits Data Evaluation Investigator Site Audit

### **FDA Inspections**

Clinical Trial Monitoring Noncompliance Issues **Regulations Guiding Inspections** Non-US Inspections What FDA Will Inspect **Common Deficiencies** Inspection Results Managing FDA Inspections **IRB/EC and CRO Inspections** 

## **Course Authors**

Carol Nash Michael Carter, MD, RP Sr. Director, Clinical Safety & Pharmacovigilance URL Pharma, Inc.